Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
2.
Acta Dermatovenerol Alp Pannonica Adriat ; 28(4): 185-186, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31855275

ABSTRACT

The cutaneous adverse effects of gemcitabine include allergic skin rash frequently associated with pruritus, alopecia, sweating, dermatitis with boils, and ulcerations. We report the case of a patient that developed inflammation of seborrheic keratoses after gemcitabine treatment.


Subject(s)
Antimetabolites, Antineoplastic/adverse effects , Deoxycytidine/analogs & derivatives , Drug Eruptions/etiology , Keratosis, Seborrheic/chemically induced , Adenocarcinoma of Lung/drug therapy , Aged , Antimetabolites, Antineoplastic/therapeutic use , Deoxycytidine/adverse effects , Deoxycytidine/therapeutic use , Female , Humans , Gemcitabine
3.
Melanoma Res ; 28(5): 475-477, 2018 10.
Article in English | MEDLINE | ID: mdl-29965880

ABSTRACT

Immune checkpoint inhibitors targeting the programmed cell death (PD)-1 receptor have dramatically changed the landscape of metastatic melanoma treatment. Nevertheless, these immuno-modulatory agents have associated side effects, including dermatologic manifestations. To this end, we report a patient with metastatic melanoma that was treated with a PD-1 inhibitor, and subsequently developed inflammation of existing seborrheic keratosis lesions and new verrucous keratoses, a cutaneous side effect that has not been previously reported to our knowledge. The etiology of seborrheic and verrucous keratoses is not well understood, although their physical and histopathologic similarities to chronic viral-derived lesions, such as human papilloma virus, suggest a potential viral association. Chronic viral infections are known to result in T-cell tolerance because of persistent antigen stimulation. PD-1 inhibition is able to reinvigorate exhausted T cells, which are accordingly able to decrease viral load. Thus, the inflammatory reaction, seen in our patient, may be the result of PD-1 inhibition reactivating virally driven T lymphocytes.


Subject(s)
Inflammation/chemically induced , Keratosis, Seborrheic/chemically induced , Melanoma/complications , Nivolumab/adverse effects , Skin Neoplasms/complications , Humans , Melanoma/pathology , Skin Neoplasms/pathology
5.
Acta Derm Venereol ; 97(2): 258-260, 2017 02 08.
Article in English | MEDLINE | ID: mdl-27353949
7.
Cutis ; 90(5): 235-6, 2012 Nov.
Article in English | MEDLINE | ID: mdl-23270192

ABSTRACT

Leser-Trélat sign is a controversial paraneoplastic phenomenon characterized by an eruption of seborrheic keratoses (SKs). We report a rare case of eruptive inflammatory SKs in a man undergoing induction chemotherapy for acute myeloid leukemia (AML). We also review the literature on Leser-Trélat sign.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Keratosis, Seborrheic/chemically induced , Keratosis, Seborrheic/diagnosis , Leukemia, Myeloid, Acute/drug therapy , Paraneoplastic Syndromes/diagnosis , Humans , Induction Chemotherapy , Keratosis, Seborrheic/complications , Keratosis, Seborrheic/pathology , Leukemia, Myeloid, Acute/complications , Male , Middle Aged , Paraneoplastic Syndromes/pathology
8.
An Bras Dermatol ; 84(4): 410-3, 2009.
Article in Portuguese | MEDLINE | ID: mdl-19851675

ABSTRACT

There are several common mucocutaneous adverse effects related to chemotherapy, either by direct cytotoxic action or by hypersensitivity to the drugs. The authors report inflammation in multiple seborrheic keratoses after chemotherapy with gemcitabine in a patient under treatment for pancreatic cancer. Moreover, they discuss the relative benignity of this event and warn about the need to correctly identify systemic chemotherapy-induced skin adverse effects.


Subject(s)
Antimetabolites, Antineoplastic/adverse effects , Deoxycytidine/analogs & derivatives , Drug Eruptions/complications , Drug Eruptions/etiology , Keratosis, Seborrheic/chemically induced , Keratosis, Seborrheic/complications , Deoxycytidine/adverse effects , Female , Humans , Middle Aged , Gemcitabine
9.
An. bras. dermatol ; 84(4): 410-413, jul.-ago. 2009. ilus, tab
Article in Portuguese | LILACS | ID: lil-529088

ABSTRACT

São diversos e comuns os efeitos mucocutâneos dos quimioterápicos, alguns por ação citotóxica, outros por hipersensibilidade ao fármaco. Os autores relatam a ocorrência de inflamação em múltiplas queratoses seborreicas pré-existentes, após terapia citorredutora com gencitabina, em paciente sob tratamento para neoplasia de pâncreas. Discutem, ainda, a benignidade do evento e alertam para a necessidade de adequada identificação dos efeitos cutâneos decorrentes da quimioterapia sistêmica.


There are several common mucocutaneous adverse effects related to chemotherapy, either by direct cytotoxic action or by hypersensitivity to the drugs. The authors report inflammation in multiple seborrheic keratoses after chemotherapy with gemcitabine in a patient under treatment for pancreatic cancer. Moreover, they discuss the relative benignity of this event and warn about the need to correctly identify systemic chemotherapy-induced skin adverse effects.


Subject(s)
Female , Humans , Middle Aged , Antimetabolites, Antineoplastic/adverse effects , Deoxycytidine/analogs & derivatives , Drug Eruptions/complications , Drug Eruptions/etiology , Keratosis, Seborrheic/chemically induced , Keratosis, Seborrheic/complications , Deoxycytidine/adverse effects
10.
Clin Exp Dermatol ; 34(8): e564-6, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19508488

ABSTRACT

A 56-year-old man with recalcitrant psoriasis was treated with efalizumab, resulting in complete clearing of his skin lesions. However, multiple brown patches and papules, in the exact distribution of the previous psoriasis plaques, appeared on his lower legs. The pathological diagnosis was seborrhoeic keratoses (SKs) with overlapping features of solar lentigo. A variety of cutaneous adverse events has been observed in patients with psoriasis treated with efalizumab. To our knowledge, appearance of SKs after such treatment has not previously been reported. This may be due to the clinical insignificance of these benign skin tumours. However, it may be speculated whether efalizumab has an unknown effect in triggering the development of SKs in patients with psoriasis, and if this could shed any light on the pathogenesis of SKs.


Subject(s)
Anti-Inflammatory Agents/adverse effects , Antibodies, Monoclonal/adverse effects , Keratosis, Seborrheic/chemically induced , Psoriasis/drug therapy , Antibodies, Monoclonal, Humanized , Humans , Keratosis, Seborrheic/pathology , Leg Dermatoses/chemically induced , Leg Dermatoses/pathology , Male , Middle Aged , Psoriasis/pathology , Treatment Outcome
11.
J Drugs Dermatol ; 3(5): 565-6, 2004.
Article in English | MEDLINE | ID: mdl-15552612

ABSTRACT

Cytarabine, used for the treatment of acute myelogenous leukemia, can cause a rare reaction of inflammation of existing seborrheic keratoses. We report a case of cytarabine induced inflammation of seborrheic keratoses mimicking a vesicular eruption in 53-year-old man with acute myelogenous leukemia.


Subject(s)
Antimetabolites, Antineoplastic/adverse effects , Cytarabine/adverse effects , Inflammation/chemically induced , Keratosis, Seborrheic/chemically induced , Humans , Keratosis, Seborrheic/pathology , Leukemia, Myeloid, Acute/drug therapy , Male , Middle Aged
12.
J Am Acad Dermatol ; 45(6 Suppl): S212-4, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11712062

ABSTRACT

The appearance of multiple seborrheic keratoses in association with underlying internal malignancy (known as the sign of Leser-Trelat) has generated much discussion and debate in the literature. However, comparatively few case reports exist that examine the appearance of multiple seborrheic keratoses associated with exfoliative erythroderma without underlying malignancy. We report 2 cases in which multiple, biopsy-proven seborrheic keratoses appeared in conjunction with erythrodermic skin eruptions. The underlying diseases in these 2 patients included psoriasis and an eczematous drug eruption; in both cases the erythroderma resolved with appropriate treatment. After resolution of the erythroderma, the newly developed seborrheic keratoses proceeded to involute and gradually fall off. Neither of the patients exhibited any evidence of internal malignancy. These cases represent the first reports of psoriasis and drug eruption as causes of erythroderma-induced transient eruptive seborrheic keratoses. Clinical and pathologic findings are consistent with previous descriptions of this entity.


Subject(s)
Drug Eruptions/diagnosis , Keratolytic Agents/adverse effects , Keratosis, Seborrheic/diagnosis , Psoriasis/drug therapy , Aged , Diagnosis, Differential , Drug Eruptions/etiology , Drug Eruptions/pathology , Female , Humans , Keratosis, Seborrheic/chemically induced , Keratosis, Seborrheic/pathology , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...